<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02670447</url>
  </required_header>
  <id_info>
    <org_study_id>1508174</org_study_id>
    <secondary_id>2015-A01756-43</secondary_id>
    <nct_id>NCT02670447</nct_id>
  </id_info>
  <brief_title>Early Identification of Patients Presenting a First Psychotic Episode, Non Answering to First Line Support Strategies</brief_title>
  <acronym>PEPsy</acronym>
  <official_title>Early Identification of Patients Presenting a First Psychotic Episode, Non Answering to First Line Support Strategies: A Multicentric Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers propose in this project to evaluate predictive factors of non response. It is&#xD;
      defined by the lack of symptomatic remission at month 3, for patients presenting a first&#xD;
      episode of psychosis. It will be performed on objective markers taken from imagery&#xD;
      techniques. The link between evolution of these markers and clinical measures will be&#xD;
      studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recently, radiological markers demonstrated a good capacity to discriminate first episode of&#xD;
      psychosis patients, that will show a bad response to treatment. Furthermore, automatic&#xD;
      learning methods were recently successfully applied to neurological data, but never for the&#xD;
      first episode psychosis patients. These powerful methods are based on multivariate analyses&#xD;
      allowing the prediction at an individual stage. The possibility to identify more precisely&#xD;
      the population of non-answering patients would allow the adaptation of the support in first&#xD;
      attention for these patients, and consequently to perform appropriate cares.&#xD;
&#xD;
      Researchers propose in this project to evaluate predictive factors of non response. It is&#xD;
      defined by the lack of symptomatic remission at month 3, for patients presenting a first&#xD;
      episode of psychosis. It will be performed on objective markers taken from imagery&#xD;
      techniques. The link between evolution of these markers and clinical measures will be&#xD;
      studied.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2022</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Score of the predictive value of the imagery markers.</measure>
    <time_frame>Month 3</time_frame>
    <description>Evaluate the predictive value for the imagery markers on the therapeutic non-answer at month 3 for patients presenting a first psychotic episode.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>First episode of psychosis patients</arm_group_label>
    <description>Patients with schizophrenia will be studied in this clinical trial, and that have never received anti-psychotic treatment. They will perform an MRI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Magnetic Resonance Imagery will be performed on patients attempted by schizophrenia. The aim of this intervention is an early detection of the non-answering patients to the primary cares.</description>
    <arm_group_label>First episode of psychosis patients</arm_group_label>
    <other_name>Magnetic Resonance Imagery</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples will be taken for every patient to make toxicological tests.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suffering of schizophrenia will be included in this study. They do not have ever&#xD;
        taken anti-psychotic treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  men and women aged 18-35 years&#xD;
&#xD;
          -  member or beneficiary of a social security scheme,&#xD;
&#xD;
          -  for women, appropriate contraception will be mandatory, as well as a negative&#xD;
             pregnancy test,&#xD;
&#xD;
          -  patients with a diagnosis of schizophrenia, schizoaffective disorder or&#xD;
             schizophreniform disorder according to the DMS V&#xD;
&#xD;
          -  having never received anti-psychotic treatment,&#xD;
&#xD;
          -  followed in the hospital or outpatient,&#xD;
&#xD;
          -  having given their written informed consent,&#xD;
&#xD;
          -  that the physical examination revealed no significant clinical abnormalities&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female patients of childbearing period without effective contraception (oral,&#xD;
             intramuscular hormonal, intrauterine device, or surgical);&#xD;
&#xD;
          -  Patients pregnant or nursing;&#xD;
&#xD;
          -  Presenting a serious somatic or neurological disease, especially Parkinson's disease,&#xD;
             epilepsy, debilitating tardive dyskinesia, cardiovascular disease, severe liver or&#xD;
             kidney;&#xD;
&#xD;
          -  Featuring against-indication for an MRI; including: metallic foreign body eye or&#xD;
             intracranial, pacemaker, heart valve, surgical clips, claustrophobia, large tattoo in&#xD;
             the upper part of the body, not compatible with 3T MRI&#xD;
&#xD;
          -  Having a history of alcohol or drug abuse in the past year;&#xD;
&#xD;
          -  Participating in another clinical trial or being in an exclusion period of the&#xD;
             previous protocol;&#xD;
&#xD;
          -  Patients likely to exhibit aggressive behavior self according to the judgment of the&#xD;
             investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric FAKRA, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric FAKRA, MD PhD</last_name>
    <phone>(0)477127885</phone>
    <phone_ext>+33</phone_ext>
    <email>eric.fakra@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carine LABRUYERE, CRA</last_name>
    <phone>(0)477124069</phone>
    <phone_ext>+33</phone_ext>
    <email>carine.labruyere@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Le Vinatier</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Thierry DAMATO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric HAESEBAERT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Romain REY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Isabelle CHEREAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre-Michel LLORCA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Mircea POLOSAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnaud POUCHON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clément DONDE-COQUELET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HÔPITAL Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Emmanuel POULET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louis SIMON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Saint Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>42100</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Eric FAKRA, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maxence RIGON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maël PULCINI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Colas MOREL-PRIEUR, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe GAULD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 28, 2016</study_first_submitted>
  <study_first_submitted_qc>January 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2016</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

